Pharmafile Logo
Pharmafocus logo
Advanced Search

Zaltrap

Showing 10 posts of 10 posts found.

NHS drops 25 treatments from Cancer Drugs Fund

January 12, 2015
Sales and Marketing Afinitor, CDF, Cancer, Cancer Drugs Fund, Eisa, Halaven, Heribulin, Jevtana, NHS, Sanofi, Zaltrap, aflibercept, cabazitaxel, everolimus

Twenty-five cancer treatments will be removed from the Cancer Drugs Fund list, NHS England has announced. Having concluded its review …

News
sanofi

Final no for Sanofi’s Zaltrap

March 25, 2014
Medical Communications, Sales and Marketing NICE, Sanofi, Zaltrap, colorectal cancer

News
Zaltrap image

Zaltrap ‘no’ from NICE

June 21, 2013
Sales and Marketing NICE, Sanofi, Zaltrap

NICE is preparing to discard Sanofi’s Zaltrap as an NHS option for treating metastatic colorectal cancer (mCRC) that is resistant …

News
sanofi_hq_reception_close

Zaltrap launched in UK

March 4, 2013
Sales and Marketing Sanofi, Zaltrap

Sanofi and Regeneron Pharmaceuticals’ bowel cancer drug Zaltrap has been launched in the UK today. Zaltrap (aflibercept) will be used …

News
regeneron image

Sanofi ups stake in Regeneron

February 13, 2013
Sales and Marketing AMD, Regeneron, Sanofi, Zaltrap

Sanofi is increasing its stake in Regeneron Pharmaceuticals by buying shares on the open market and from existing shareholders. The …

News

Sanofi celebrates EU approvals

February 5, 2013
Sales and Marketing Lyxumia, Sanofi, Zaltrap, diabetes

Sanofi is celebrating after diabetes treatment Lyxumia (lixisenatide) and metastatic colorectal cancer (mCRC) drug Zaltrap received authorisation in Europe. The …

News
Zaltrap image

Sanofi’s Zaltrap data published

October 8, 2012
Research and Development, Sales and Marketing Erbitux, Sanofi, Stivarga, Zaltrap, avastin

Detailed data from the Phase III trial of Sanofi’s newly-licenced anti-VEGF cancer drug Zaltrap, co-marketed with Regeneron, has been published. …

News

Regeneron to expand workforce at New York facility

August 8, 2012
Manufacturing and Production Arcalyst, Eylea, Regeneron, Zaltrap

Buoyant product sales at US biotech Regeneron have prompted the company to undertake a recruitment drive at its manufacturing facility …

News

Sanofi’s colorectal cancer drug gains FDA approval

August 6, 2012
Sales and Marketing FDA, Sanofi, Zaltrap, colorectal cancer

The FDA has approved Sanofi and Regeneron’s new oncology drug Zaltrap for aggressive forms of colorectal cancer.Zaltrap (ziv-aflibercept), in combination …

News

FDA grants priority review for Sanofi cancer drug

April 5, 2012
Research and Development, Sales and Marketing Erbitux, FDA, Regeneron, Sanofi, Zaltrap, colorectal cancer, prostate cancer

The FDA has granted Sanofi and partner Regeneron priority review for their colorectal cancer drug Zaltrap. Zaltrap (aflibercept) is seeking a …

News
The Gateway to Local Adoption Series

Latest content

Faron Pharmaceuticals appoints Heikki Jouttijärvi as Chief Technical Officer

April 2, 2026

Cambridge’s Grassroots Life Sciences Showcase Branches Out to Oxford & London

April 1, 2026

Doccla appoints Michael Macdonnell as Chief Strategy & Growth Officer and Deputy CEO

April 1, 2026

Bramacare launches new AI platform to improve eating disorder care

March 31, 2026

Doccla appoints Jonathan Serjeant as Chief Medical Officer

March 31, 2026